NephroPlus Listed
Dialysis-care center chain operating in-clinic, home, and mobile dialysis services plus a dialysis technician/nursing training academy across India, Nepal, the Philippines, and Uzbekistan. Listed on NSE/BSE in December 2025 (as Nephrocare Health Services Limited).
Valuation
Returns
Per share
Growth · year on year
Ownership
Price and ratios are compiled from the exchange and third-party market data, cached and refreshed through the day — they are not Atlas facts and are not investment advice. Where a ratio is computed on more than one basis (for example standalone versus trailing-twelve-month), each is shown separately rather than averaged into a single number.
How this score is calculated
| Measure | Value | Scores | Source |
|---|---|---|---|
| P/E What the market pays for each rupee of earnings. Lower is cheaper — but a low P/E can also mean the market expects earnings to fall. |
0.00 | 100/100 | Market data |
| P/B Price against book value. Most meaningful for banks and asset-heavy businesses; software and consumer brands trade high here for good reasons. |
7.29 | 25/100 | Market data |
| ROE Return on equity — profit generated per rupee of shareholder capital. Sustained high ROE is the clearest single marker of a good business. |
-1.09 | 0/100 | Market data |
| ROCE Return on capital employed — the same idea including debt, so it is harder to flatter with leverage. |
5.61 | 25/100 | Market data |
| Profit growth Year-on-year growth in profit. Weighted above sales growth because profitable growth is the harder thing to do. |
-123.54 | 0/100 | Market data |
| Sales growth Year-on-year growth in revenue. |
15.85 | 75/100 | Market data |
| Revenue growth · filed Year-on-year revenue growth computed from the fiscal-year figures we filed ourselves and cited to a real disclosure, not a market data feed. |
29.20 | 100/100 | Atlas |
| Profit trend · filed Whether profit is improving, from the same filed figures. A swing from loss to profit scores highest; a swing from profit into loss scores lowest; a narrowing loss still scores better than a widening one. |
Swung to profit | 100/100 | Atlas |
| Promoter holding How much of the company its founders and controlling group still own. Higher usually means their money moves with yours. |
63.85 | 100/100 | Market data |
The Atlas Score is our own arithmetic on the published figures above — nothing is hidden and nothing is bought in. It weighs quality and growth at 30% each, valuation at 25% and ownership at 15%, scoring each measure against fixed bands. Growth blends third-party market data with the fiscal-year figures we file and cite ourselves, so a company we have researched more deeply scores on richer evidence. A measure we could not fetch is left out of the average rather than counted as a zero. It is a summary of the numbers, not a recommendation, not a price target, and not advice about your circumstances.
NephroPlus: Funding Rounds
| Date | Round | Amount | Investors | Source |
|---|---|---|---|---|
| 6 May 2024 | Series F | $103 Mn | Quadria Capital | source |
| 4 Jan 2023 | Debt | ₹69.5 Cr | Asian Development Bank | source |
| 13 Dec 2021 | Series E | $24 Mn | IIFL Asset Management Bessemer Venture Partners Investcorp | source |
| 25 Nov 2019 | Series D | $45 Mn | Investcorp | source |
| 24 Aug 2016 | Series C | ₹100 Cr | International Finance Corporation (IFC) SeaLink Capital Partners | source |
| 1 Dec 2015 | Debt | Undisclosed | Trifecta Capital | source |
| 1 Jun 2014 | Series B | $10 Mn | Bessemer Venture Partners International Finance Corporation (IFC) | source |
| 1 Jan 2011 | Series A | $4.25 Mn | Bessemer Venture Partners | source |
Acquisitions
| Date | Acquirer | Acquired | Amount | Source |
|---|---|---|---|---|
| 13 Oct 2020 | NephroPlus | Royal Care Dialysis Centers, Inc | Undisclosed | source |
| 5 Nov 2018 | NephroPlus | DaVita Care India | Undisclosed | source |
Recent Signals
-
17 Dec 2025 · financial
Nephrocare Health Services (NephroPlus) lists on NSE and BSE, debuts at a premium source
News on NephroPlus
No coverage of NephroPlus linked yet.
L Litmus · by Lapaas
Got an idea like this one? Validate it with the same 9-block framework, free.
Start Free ValidationFAQs on NephroPlus
Who founded NephroPlus?
NephroPlus was founded by Vikram Vuppala, Kamal D. Shah, Sandeep Gudibanda in 2010.
How much funding has NephroPlus raised?
NephroPlus has raised $209.8 Mn across 8 tracked funding round(s), most recently on 2024-05-06. Figures are compiled from cited public sources.
Who are the investors in NephroPlus?
Investors in NephroPlus include Quadria Capital, Asian Development Bank, IIFL Asset Management, Bessemer Venture Partners, Investcorp.
What does NephroPlus do?
Dialysis-care center chain operating in-clinic, home, and mobile dialysis services plus a dialysis technician/nursing training academy across India, Nepal, the Philippines, and Uzbekistan. Listed on NSE/BSE in December 2025 (as Nephrocare Health Services Limited).
Where is NephroPlus headquartered?
NephroPlus is headquartered in Hyderabad, Telangana, India.
What is NephroPlus's business model?
NephroPlus's core value proposition centers on Affordable, high-quality dialysis care, Comfort, care and safety at every step, Redefining dialysis with modern infrastructure.
How does NephroPlus make money?
NephroPlus's cited revenue streams include Dialysis treatment service fees, Government PPP dialysis contracts, International PPP contracts (Uzbekistan).